- Home
- ELYM
as 07-26-2024 4:00pm EST
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 452.1M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 268.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.35 - $11.55 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Eliem Therapeutics Inc (ELYM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 19 '24 | Sell | $7.98 | 30,000 | $239,400.00 | 31,317 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 19 '24 | Sell | $8.07 | 39,005 | $314,770.35 | 61,317 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 19 '24 | Sell | $7.24 | 50,000 | $362,000.00 | 100,322 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 19 '24 | Sell | $7.09 | 10,201 | $72,325.09 | 150,322 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 16 '24 | Sell | $7.13 | 50,000 | $356,500.00 | 202,306 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 5 '24 | Sell | $7.06 | 12,342 | $87,134.52 | 450,614 | SEC Form 4 |
| Morisset Valerie | ELYM | EVP, R&D AND CSO | Jul 1 '24 | Sell | $6.76 | 50,000 | $338,000.00 | 462,956 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | ELYM | Director10% Owner | Jun 27 '24 | Buy | $3.84 | 1,059,375 | $4,068,000.00 | 2,866,375 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | ELYM | Director10% Owner | Jun 27 '24 | Buy | $3.84 | 11,949,171 | $45,884,816.64 | 23,521,757 | SEC Form 4 |
| Pimblett Emily | ELYM | CHIEF ACCOUNTING OFFICER | Jun 18 '24 | Sell | $7.21 | 1,245 | $8,982.05 | 3,755 | SEC Form 4 |
Latest Eliem Therapeutics Inc News
ELYM Breaking Stock News: Dive into ELYM Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
Daily – Vickers Top Buyers & Sellers for 07/24/2024
GuruFocus.com
3 days ago
Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares
GuruFocus.com
7 days ago
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
MT Newswires
7 days ago
Eliem Therapeutics Insider Sold Shares Worth $289,492, According to a Recent SEC Filing
GuruFocus.com
9 days ago
EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)
Argus Research
10 days ago
Daily – Vickers Top Buyers & Sellers for 07/17/2024
GuruFocus.com
10 days ago
Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...
MT Newswires
14 days ago
Eliem Therapeutics Files Prospectus for Sale of Up to 36.8 Million Shares by Stockholders
Compare ELYM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELYM Eliem Therapeutics Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.